Slowing the Progression of

Macular Degeneration

Mission for Vision

Media and Investor Relations Contact: Jennifer Wu /ir@belitebio.com

Tim McCarthy /tim@lifesciadvisors.com

Disclaimer

This presentation has been prepared by Belite Bio, Inc (the "Company") solely for information purposes. This presentation does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended (the "Securities Act"). This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. No securities of the Company may be offered or sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act and the rules and regulations thereunder. Any public offering of the Company's securities to be made in the United States will be made by means of a statutory prospectus as specified under the Securities Act. The prospectus will contain detailed information about the Company, its subsidiaries and consolidated affiliated entities and its management as well as the consolidated financial statements of the Company and risks and uncertainties associated with the Company's business and industry. Any decision to purchase the Company's securities in the offering for sale in the United States or anywhere else should be made on the basis of the information contained in the statutory prospectus included in the offering memorandum. The prospectus will be made publicly available in due course and can be obtained free of charge from the SEC's website at www.sec.gov.

Certain information contained in this presentation was obtained from various sources, including third parties, and has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the sources presented or contained herein. By attending this presentation, participants acknowledge and agree that none of the Company or any of its affiliates, shareholders, directors, employees, agents, advisors, representatives or underwriters will be liable (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation.

This presentation speaks as of the date hereof. The information presented or contained in this presentation is subject to change without notice. Neither the delivery of this presentation nor any further discussions of the Company or any of its affiliates, shareholders, directors, employees, agents, advisors, representatives or underwriters with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

This presentation contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to projected financial and operating results, market opportunity and business prospects of the Company. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident" or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, many of which are beyond the Company's control. The Company and its affiliates, directors, officers, employees, advisors, representatives and underwriters assume no obligation to and do not undertake to update such forward-looking statements to reflect future events or circumstances.

By attending this presentation, participants agree not to remove this document, or any materials provided in connection herewith, from the conference room where such documents are provided. Participants agree further not to photograph, copy or otherwise reproduce these materials in any form or pass on these materials to any other person for any purpose. Participants must return this presentation and all other materials provided in connection herewith to the Company at the completion of the presentation.

BE L IT E BIO / 2

At-a-Glance

"Bringing Hope to Incurable Blindness"

As of 2022/7/21

Belite Bio, Inc

Share Symbol

BLTE

Stock Exchange

NASDAQ

Stock Price

$ 41.51

Shares Outstanding

24.87 million

Market Cap

$ 1,032.35 million

BE L IT E BIO / 3

Leadership

Management

Tom Lin, MMED, PhD, MBA

(Chairman, CEO)

  • 10 years of executive management role in biotech, including 2 IPO
  • Over 10 new drug developments in multiple therapeutic areas, including Ophthalmology, CNS, Cardiovascular, Oncology, Immuno-Oncology, Immunotherapies, Immunosuppressants
  • University of Sydney, University of Melbourne, Harvard Medical School, Columbia University, London Business School, HK University

Nathan Mata, PhD

(CSO)

  • 15+ years of ophthalmic drug development experience across numerous indications including 2 NDAs for topical therapeutics (Durezol® and Zirgan®)
  • Led the clinical development efforts for first RBP antagonist in advanced dry AMD and first visual cycle modulator in advanced dry AMD and STGD
  • Introduced the industry's first Stargardt's ABCA4 knockout mice model
  • University of Texas

Jane Chiu, MS

(VP, Clinical Operations)

  • 25 years clinical operations experience in multiple therapeutical area
  • 15+ years as President/Managing Director of multinational CRO, conducting over 100 studies
  • 10+ years of clinical operations experience in global pharma (Astellas, Bayer, Pfizer)
  • Warwick University

H.Y. Chuang, CFA, MBA, FRM

(CFO)

  • 11 years of capital market experience, closed more than US$32 billion transactions
  • Wanda, Suning, CITIC Securities
  • Columbia University, London Business School, HK University

BE L IT E BIO / 4

Belite Bio Opportunity

Oral treatment for an unmet market

Development of lead asset

  • Belite Bio's lead asset LBS-008is a novel, orally administered, Retinol Binding Protein 4
    ("RBP4") antagonist intended to slow or halt progression of vision loss in Stargardt disease (STGD1) and dry AMD. A Phase 3 trial has been initiated in adolescent STGD1 patients and a Phase 2/3 trial in dry AMD is planned in 2022.
  • Granted Fast Track Designation, Rare Pediatric Disease in US / Orphan Drug Disease designation in US and EU for STGD1.
  • Priority Review Voucher (PRV) eligible, vouchers have sold for $80M-$125M.
  • Currently no approved treatments for either STGD1 or dry AMD, significant market opportunity to become Standard of Care.
  • Ongoing 2-yearPhase 2 trial (6 months of reported interim safety data and preliminary efficacy data) in STGD1. Goal is to halt or slow disease progression in early-onset patients.

Established human proof-of-conceptdata from a 2-year, Phase 2 trial of fenretinide (a retinoid-based RBP4 antagonist) in advanced dry AMD.

  • Clinical development approach endorsed by US NIH, specifically to treat dry AMD.
  • UK NIHR's 2018 systematic review of >7,000 publications recommends RBP4 antagonists as a priority for clinical development to treat both STGD1 and dry AMD.
  • Highly experienced senior management team supported by world-renownedadvisory board and influential key opinion leaders with decades of clinical development experience.

BE L IT E BIO / 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Belite Bio Inc. published this content on 27 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2022 08:21:08 UTC.